{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:14:50Z","timestamp":1788257690004,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1002\/jps.24651","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T21:36:04Z","timestamp":1443476164000},"page":"4207-4216","source":"Crossref","is-referenced-by-count":49,"title":["Drug\u2013Drug Molecular Salt Hydrate of an Anticancer Drug Gefitinib and a Loop Diuretic Drug Furosemide: An Alternative for Multidrug Treatment"],"prefix":"10.1016","volume":"104","author":[{"given":"Shridhar H.","family":"Thorat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjusha V.","family":"Patwadkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manohar V.","family":"Badiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh G.","family":"Gonnade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1002\/jps.24651_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/cm00001a005","article-title":"Hydrogen-bond directed cocrystallization as a tool for designing acentric organic solids","volume":"1","author":"Etter","year":"1989","journal-title":"Chem Mater"},{"issue":"4","key":"10.1002\/jps.24651_bb0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/ar00172a005","article-title":"Encoding and decoding hydrogen-bond patterns of organic compounds","volume":"23","author":"Etter","year":"1990","journal-title":"Acc Chem Res"},{"issue":"17","key":"10.1002\/jps.24651_bb0015","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1002\/1521-3773(20010903)40:17<3240::AID-ANIE3240>3.0.CO;2-X","article-title":"\u201cTotal synthesis\u201d supramolecular style: Design and hydrogen-bond-directed assembly of ternary supermolecules","volume":"40","author":"Aaker\u00f6y","year":"2001","journal-title":"Angew Chem Int Ed"},{"issue":"9","key":"10.1002\/jps.24651_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1039\/b708112j","article-title":"What is a co-crystal?","volume":"9","author":"Bond","year":"2007","journal-title":"Cryst Eng Comm"},{"issue":"6","key":"10.1002\/jps.24651_bb0025","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/cg060838j","article-title":"Diversity in single- and multiple-component crystals. The search for and prevalence of polymorphs and cocrystals","volume":"7","author":"Stahly","year":"2007","journal-title":"Cryst Growth Des"},{"issue":"3","key":"10.1002\/jps.24651_bb0030","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1021\/cg800764n","article-title":"Recent advances in understanding the mechanism of cocrystal formation via grinding","volume":"9","author":"Fri\u0161\u010di\u0107","year":"2009","journal-title":"Cryst Growth Des"},{"issue":"72","key":"10.1002\/jps.24651_bb0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1039\/b505883j","article-title":"Building co-crystals with molecular sense and supramolecular sensibility","volume":"7","author":"Aakeroy","year":"2005","journal-title":"Cryst Eng Comm"},{"issue":"6","key":"10.1002\/jps.24651_bb0040","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1021\/cg900129f","article-title":"Pharmaceutical cocrystals and their physicochemical properties","volume":"9","author":"Schultheiss","year":"2009","journal-title":"Cryst Growth Des"},{"issue":"3","key":"10.1002\/jps.24651_bb0045","first-page":"99","article-title":"Pharmaceutical co-crystals\u2014A review","volume":"50","author":"Sekhon","year":"2009","journal-title":"Ars Pharm"},{"issue":"3","key":"10.1002\/jps.24651_bb0050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jps.20578","article-title":"Pharmaceutical co-crystals","volume":"95","author":"Vishweshwar","year":"2006","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1002\/jps.24651_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/mp060126o","article-title":"Cocrystal or salt: Does it really matter?","volume":"4","author":"Aaker\u00f6y","year":"2007","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1002\/jps.24651_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.addr.2003.10.020","article-title":"High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids","volume":"56","author":"Morissette","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"issue":"1-3","key":"10.1002\/jps.24651_bb0065","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.molstruc.2011.10.004","article-title":"Co-crystals of an agrochemical active\u2014 A pyridine-amine synthon for a thioamide group","volume":"1006","author":"Nauha","year":"2011","journal-title":"J Mol Struct"},{"issue":"9","key":"10.1002\/jps.24651_bb0070","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1021\/cg3010882","article-title":"High power explosive with good sensitivity: A 2:1 cocrystal of CL-20:HMX","volume":"12","author":"Bolton","year":"2012","journal-title":"Cryst Growth Des"},{"issue":"10","key":"10.1002\/jps.24651_bb0075","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1039\/c2ce05796d","article-title":"Crystal engineering of energetic materials: Co-crystals of CL-20","volume":"14","author":"Millar","year":"2012","journal-title":"Cryst Eng Comm"},{"issue":"38","key":"10.1002\/jps.24651_bb0080","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1002\/anie.201104164","article-title":"Improved stability and smart-material functionality realized in an energetic cocrystal","volume":"50","author":"Bolton","year":"2011","journal-title":"Angew Chem Int Ed"},{"issue":"6575","key":"10.1002\/jps.24651_bb0085","first-page":"1","article-title":"Continuous engineering of nano-cocrystals for medical and energetic applications","volume":"4","author":"Spitzer","year":"2014","journal-title":"Sci Rep"},{"key":"10.1002\/jps.24651_bb0090","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1021\/cg200492w","article-title":"Solubility advantage of amorphous drugs and pharmaceutical cocrystals","volume":"11","author":"Babu","year":"2011","journal-title":"Cryst Growth Des"},{"issue":"1","key":"10.1002\/jps.24651_bb0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/cg701022e","article-title":"Polymorphism in carbamazepine cocrystals","volume":"8","author":"Porter","year":"2008","journal-title":"Cryst Growth Des"},{"issue":"12","key":"10.1002\/jps.24651_bb0100","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1021\/cg3012124","article-title":"Cocrystal hydrate of an antifungal drug, griseofulvin, with promising physicochemical properties","volume":"12","author":"Aitipamula","year":"2012","journal-title":"Cryst Growth Des"},{"issue":"17","key":"10.1002\/jps.24651_bb0105","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1039\/c3ce42008f","article-title":"Polymorphism in cocrystals: A review and assessment of its significance","volume":"16","author":"Aitipamula","year":"2014","journal-title":"Cryst Eng Comm"},{"key":"10.1002\/jps.24651_bb0110","unstructured":"List of GRAS compounds. Accessed March 8, 2015, at: http:\/\/www.accessdata.fda.gov\/scripts\/fdcc\/?set=SCOGS."},{"issue":"20","key":"10.1002\/jps.24651_bb0115","first-page":"5749","article-title":"ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy","volume":"62","author":"Wakeling","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1002\/jps.24651_bb0120","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/jps.22805","article-title":"Novel furosemide cocrystals and selection of high solubility drug forms","volume":"101","author":"Goud","year":"2012","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1002\/jps.24651_bb0125","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1021\/cg100098z","article-title":"Conformational and synthon polymorphism in furosemide (Lasix)","volume":"10","author":"Babu","year":"2010","journal-title":"Cryst Growth Des"},{"key":"10.1002\/jps.24651_bb0130","unstructured":"The American Society of Health-System Pharmacists. Accessed April 3, 2011, at: https:\/\/en.wikipedia.org\/wiki\/Furosemide#cite_note-AHFS-4."},{"key":"10.1002\/jps.24651_bb0135","unstructured":"http:\/\/www.drugs.com\/monograph\/furosemide.html."},{"issue":"15","key":"10.1002\/jps.24651_bb0140","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J Clin Oncol"},{"issue":"37","key":"10.1002\/jps.24651_bb0145","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.1039\/C4CE01446D","article-title":"Capturing a novel metastable polymorph of the anticancer drug gefitinib","volume":"16","author":"Thorat","year":"2014","journal-title":"Cryst Eng Comm"},{"issue":"2","key":"10.1002\/jps.24651_bb0150","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/cg8007359","article-title":"Co-crystals of the anti-HIV drugs lamivudine and zidovudine","volume":"9","author":"Bhatt","year":"2009","journal-title":"Cryst Growth Des"},{"issue":"13","key":"10.1002\/jps.24651_bb0155","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1039\/c0ce00842g","article-title":"Drug\u2013drug cocrystals: Temperature-dependent proton mobility in the molecular complex of isoniazid with 4-aminosalicylic acid","volume":"13","author":"Grobelny","year":"2011","journal-title":"Cryst Eng Comm"},{"issue":"9","key":"10.1002\/jps.24651_bb0160","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/cg500668a","article-title":"Preparation and solid-state characterization of dapsone drug\u2013drug co-crystals","volume":"14","author":"Jiang","year":"2014","journal-title":"Cryst Growth Des"},{"issue":"11","key":"10.1002\/jps.24651_bb0165","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1021\/cg200288b","article-title":"Pyrazinamide-diflunisal: A new dual-drug co-crystal","volume":"11","author":"\u00c9vora","year":"2011","journal-title":"Cryst Growth Des"},{"key":"10.1002\/jps.24651_bb0170","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2004.09.064","article-title":"Side effects of therapy","volume":"22","author":"Kumasaka","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1002\/jps.24651_bb0175","first-page":"263","article-title":"Hypertension in cancer patients","volume":"38","author":"Mouhayar","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1002\/jps.24651_bb0180","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2008.18.6015","article-title":"Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study","volume":"27","author":"Natale","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1002\/jps.24651_bb0185","series-title":"Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof","author":"Gorantla","year":"2014"},{"key":"10.1002\/jps.24651_bb0190","series-title":"APEX2, SAINT, and SADABS","author":"Bruker","year":"2006"},{"key":"10.1002\/jps.24651_bb0195","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","article-title":"A short history of SHELX","volume":"A64","author":"Sheldrick","year":"2008","journal-title":"Acta Cryst"},{"issue":"2","key":"10.1002\/jps.24651_bb0200","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1107\/S0021889807067908","article-title":"Mercury CSD 2.0\u2014New features for the visualization and investigation of crystal structures","volume":"41","author":"Macrae","year":"2008","journal-title":"J Appl Cryst"},{"issue":"1","key":"10.1002\/jps.24651_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1107\/S0021889802022112","article-title":"Single-crystal structure validation with the program PLATON","volume":"36","author":"Spek","year":"2003","journal-title":"J Appl Cryst"},{"issue":"5","key":"10.1002\/jps.24651_bb0210","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1021\/cg901345u","article-title":"Structure\u2212stability relationships in cocrystal hydrates: Does the promiscuity of water make crystalline hydrates the nemesis of crystal engineering?","volume":"10","author":"Clarke","year":"2010","journal-title":"Cryst Growth Des"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T03:26:49Z","timestamp":1537327609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0022354915000817"],"URL":"https:\/\/doi.org\/10.1002\/jps.24651","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}